NORD'S MISSION

The National Organization for Rare Disorders, Inc., (NORD) is a unique federation of voluntary health organizations dedicated to helping people with rare "orphan" diseases and assisting the organizations that serve them. NORD is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and services.

THE BEGINNING

NORD was launched in 1983 as an outgrowth of a unified effort by rare-disease support groups to encourage the pharmaceutical industry to develop new and better treatments for rare "orphan" disorders. At the time, companies were not willing to devote their resources to rare disorders because of the limited commercial potential for these therapies. Consequently, voluntary health agencies and support groups banded together to urge passage of federal legislation that would provide appropriate incentives for pharmaceutical companies to develop drugs for rare disorders. In 1983, these efforts resulted in passage of the Orphan Drug Act, and NORD came into existence as a national, non-profit voluntary health agency, dedicated to the welfare of individuals and family members affected by rare diseases.

NORD TODAY

Since its beginnings in 1983, NORD has grown and expanded its services for patients, families, support groups, and medical professionals. It is now a federation of more than 130 not-for-profit health organizations serving people with rare disorders. Each year, hundreds of thousands of affected individuals and their families, as well as support groups, health care and human service professionals, and advocates for people with disabilities rely on NORD's assistance, information, leadership, and services. **NORD**[®]

National Organization for Rare Disorders, Inc.®



NORD[®]

P.O. Box 1968 Danbury, CT 06813-1968 PHONE: (203) 744-0100 FAX: (203) 798-2291 Toll-Free: (800) 999-NORD E-MAIL: orphan@rarediseases.org WEB SITE: http://www.rarediseases.org

...out of the darkness, into the light...®



INFORMATION AND REFERRAL SERVICES

NORD's primary mission is to provide information to patients, members of their families, the medical community, other professionals such as educators and social workers, and the public at large, to increase understanding and awareness of rare disorders. Its primary mission also includes providing referrals to appropriate organizations and agencies. For these purposes, NORD offers the following:

WEB SITE

NORD's web site (<u>www.rarediseases.org</u>) receives approximately 100,000 visits each month. It provides information about rare diseases, patient organizations, and current news of interest to the rare-disease community.

NORD's Rare Disease Database (RDB)

This database provides information in understandable language on more than 1,135 rare disorders for patients and their families. The reports can be downloaded from NORD's web site or sent through the mail to people who call or write to NORD.

NORD's Organizational Database (ODB)

This database provides descriptions and contact information for approximately 2,000 patient organizations, support groups, clearinghouses, registries, and government agencies that serve individuals and families affected by rare disorders. It is available for unlimited searching on NORD's web site. In addition, referrals are made over the phone or through the mail to people who do not have access to the web.

Publications

NORD's publications include *The NORD Guide to Rare Disorders,* a 900-page medical text for physicians published in 2003 by Lippincott, Williams & Wilkins; the *NORD Resource Guide*, which is a printed version of the Organizational Database; the *Orphan Disease Update* and *NORD Online* newsletters; and *The Physician's Guide* series of free booklets for medical professionals.

MEDICAL RESEARCH

There continues to be a serious shortage of funding for clinical research on orphan diseases. NORD attempts to fill this void by providing seed grants to academic scientists for research on potential new treatments for rare disorders, advocating for increased government research funds, and referring affected individuals to clinical trials and genetic investigations. NORD's funding and advocacy have enabled researchers to develop breakthrough treatments that have dramatically improved the length and quality of life for thousands of children and adults with rare disorders.

PATIENT SERVICES

NORD helps individuals and family members who need assistance in accessing benefits and services in their local communities. A genetic counselor and a nurse are on staff to provide individualized help to people coping with complicated medical services.

MEDICATION ASSISTANCE PROGRAMS

NORD's Medication Assistance Programs provide certain prescription pharmaceuticals to needy uninsured patients who cannot afford to purchase them. In general, these are expensive drugs for chronic conditions. NORD also administers Expanded Access Programs for certain experimental drugs that are on the FDA priority review track, as well as limited and/or emergency access programs for certain medications that are in limited supply.

FAMILY NETWORKING PROGRAM

NORD's Family Networking Program puts individuals and/or family members who are affected by the same rare disorders in touch with each other. In addition to promoting mutual support and the exchange of information, "networking" promotes the formation of new voluntary health agencies for specific rare diseases.

ADVOCACY

NORD continues to play a vital, prominent role in Washington, DC, addressing public policy issues on behalf of families with rare diseases, particularly when government programs and policies do not adequately address their needs. Moreover, NORD has played a crucial role worldwide in increasing recognition of rare disorders and seeking to minimize their impact on the lives of patients and familes.


National Organization for Rare Disorders, Inc. Statement of Financial Position December 31, 2003, and December 31, 2002

	2003	2002	
ASSETS			
Current Assets:			
Cash and equivalents	\$5,117,306	3,997,902	
Investments	1,028,698	872,517	
Accounts receivable, net	210,892	135,555	
Prepaid expenses			
(and other current assets)	131,856	8,202	
Total current assets	6,488,752	5,014,176	
Property and equipment	445,636	426,597	
Less accumulated depreciation			
and amortization	356,904	328,250	
Net property and equipment	88,732	98,347	
Security deposits	18,062	18,062	
	6,595,546	5,130,585	

LIABILITIES AND NET ASSETS

Liabilities:		
Accounts payable and		
accrued expenses	50,859	82,325
Research grants payable	776,833	534,384
Total Liabilities	827,692	616,709
Net assets:		
Unrestricted	4,259,770	2,607,865
Temporarily restricted	1,508,084	1,906,011
Total net assets	5,767,854	4,513,876
	\$6,595,546	5,130,585

Note: The Statements of "Financial Position" and "Activities" have been audited by a Certified Public Accountant.



National Organization for Rare Disorders, Inc. Statement of Activities for the Years Ended December 31, 2003, and 2002

	2003	2002			
REVENUE AND SUPPORT	1				
Indigent care drug programs	\$1,354,238	840,544			
Contributions and bequests	834,380	1,365,609			
Special events revenue	544,445	397,552			
Government and other grants	394,910	529,352			
Investment incomes, including					
unrealized gains (losses)	148,523	30,870			
Membership dues	105,436	85,794			
Sales and distribution of materials					
and services to the public	94,781	98,449			
Royalty income	65,923	58,239			
Net assets released					
from restrictions	1,738,202	1,343,524			
Total revenue and support	5,280,838	4,749,933			
EXPENSES					
Program Services:					
Patient services	906,410	632,127			
Education	940,915	1,051,868			
Technical assistance	81,089	17,809			
Research	1,079,516	923,296			
Advocacy	49,667	77,618			
Total program services	3,057,597	2,702,718			
Supporting services:					
Management and general	319,842	340,181			
Fundraising	161,070	191,980			
Direct cost of donor benefits	90,424	48,290			
Total supporting services	571,336	580,451			
Total expenses	3,628,933	3,283,169			
Increase in unrestricted net assets	1,651,905	1,466,764			
TEMPORARILY RESTRICTED NET ASSETS					
Contributions and grants	1,340,275	1,934,394			
Satisfaction of program					
restrictions	(1,738,202)	(1,343,524)			
Increase (decrease) in temporarily r	estricted net assets				
	(397,927)	590,870			
Change in net assets	1,253,978	2,057,634			
Change in net assets					

HOW FUNDS WERE DISBURSED IN 2003

4,513,876

5,767,854

Net assets-beginning of year

Net assets-end of year



2,456,242

4,513,876



20th ANNIVERSARY YEAR

Dear Friend of NORD:

We celebrated 20 years of progress during 2003, the 20th anniversary year for NORD and the *Orphan Drug Act*. At a gala in the spring, and throughout the year, we took time to reflect upon the achievements of the past two decades and look ahead to the challenges of the future.

NORD and the Orphan Drug Act are linked historically because they came into being at about the same time through the efforts of many of the same people. During the 10 years before the Orphan Drug Act was passed, only 10 new treatments were developed for rare diseases. In the 20 years since then, more than 1,100 new therapies have entered the research pipeline and 250 have been approved for marketing in the United States. This law has truly made a difference for people with rare diseases!

NORD has made a difference, too. Launched originally as a telephone and mail information clearinghouse, it has grown and added services over the years. Today, it maintains a news-oriented web site, administers medication assistance programs, provides publications for medical professionals, and oversees research grants and fellowships, all while continuing its core mission of education and referrals for patients and their families.

Highlights of 2003 include the following:

- NORD hosted a major conference on scientific, legal, regulatory, and economic issues related to generic biologics, and later published a white paper summarizing the proceedings.
- NORD administered 24 medication assistance programs for 18 pharmaceutical and biotechnology companies. These programs make expensive treatments available to uninsured patients who otherwise could not afford them. In 2003, NORD gave away more than \$38.2 million in drug assistance.
- NORD awarded 21 research grants and fellowships with a total value of \$768,134 during 2003, the highest number of any year to date. The grants provide seed money for promising research that might otherwise go unfunded.
- NORD added three new booklets to its free series for physicians. They are *The Physician's Guide to Pompe Disease, The Physician's Guide to Multiple System Atrophy,* and *The Physician's Guide to Hereditary Ataxia.*
- NORD's advocacy in Washington, DC, helped make possible the establishment, by the National Institutes of Health (NIH), of a Rare Diseases Clinical Research Network with \$51 million in grant funding over five years.
- NORD organized workshops in San Francisco and New York, sponsored by the NIH Office of Rare Diseases, to teach leaders of patient organizations how to access resources at the NIH.

Anniversaries help us focus on what has been accomplished...and what still remains to be done. The needs of rare-disease patients and families are many and complex. With your continued support, NORD will be able to meet those needs for many years to come.

Sincerely,

Abbey S. Meyers President James Broatch Chairman, Board of Directors

2002 - 2003 Board of Directors

CHAIR James Broatch Reflex Sympathetic Dystrophy Syndrome Association of America VICE CHAIR Carolyn Asbury, PhD Individual SECRETARY Estelle Benson Guillain Barre Syndrome Foundation, Int. TREASURER Kimberly Symonds Families With Spinal Muscular Atrophy

DIRECTORS AT LARGE

Tamara Asseyev Individual Karen Ball Sturge-Weber Foundation Edward Boyer Mercy Medical Airlift Beth Coimbra The Erythromelalgia Association Javne Gershkowitz National Tay-Sachs & Allied Diseases Association Jovce Wilcox Graff Von Hippel-Lindau Family Alliance Josephine Grima, PhD National Marfan Foundation Nancy Harris Individual Christopher Jennings Individual Judy Kaplan Late-Onset Tay-Sachs Foundation Ellen Pam Katz Society for Progressive Supranuclear Palsy Sue Levi-Pearl Tourette Syndrome Association Desiree Lyon American Porphyria Foundation Donna Rice Foundation for Ichthyosis & Related Skin Types Frank Sasinowski Individual H. Ascher Sellner, MD Wilson's Disease Association

Agnes Varis Individual

THE NORD MEDICAL ADVISORY COMMITTEE

Sami I. Said, MD (Chair) Professor, Pulmonary & Critical Care Medicine State University of New York Stony Brook Health Science Center

Associate Chief of Staff, VA Medical Center, Northport, NY



Frederick Askari, MD, PhD Assistant Professor of Medicine University of Michigan Medical Center

Garrett E. Bergman, MD Vice President, Research & Development Octagen Corporation

Roscoe O. Brady, MD Chief, Development & Metabolic Neurology Branch National Institute of Neurological Disorders & Stroke National Institutes of Health

Mitchell F. Brin, MD Vice President Botox/Neurology Allergan Pharmaceuticals

Robert Campbell Jr., MD Associate Professor of Orthopedics The University of Texas Health Science Center of San Antonio

Martha Carlson, MD, PhD Clinical Assistant Professor Director, Pediatric Neurology Metabolic Clinic University of Michigan

Mervyn L. Elgart, MD Clinical Professor of Dermatology, Medicine, and Pediatrics (Retired) The George Washington University School of Medicine

Hugo Moser, MD Director, Neurogenetics Research Center Kennedy Krieger Institute University Professor of Neurology and Pediatrics The Johns Hopkins University

Mary Jean Sawey, PhD Associate Medical Director Alliance for Scientific Affairs and Publications

Mendel Tuchman, MD

Professor of Pediatrics, Biochemistry and Molecular Biology Mary Elizabeth McGehee Joyce Chair for Genetic Research Children's National Medical Center The Genera Washington

The George Washington University

Susan Winter, MD Chief, Metabolic Genetics Services Valley Children's Hospital, Madera, CA